Results 141 to 150 of about 10,401 (200)

Early real-life outcomes of dupilumab and mepolizumab in patients with uncontrolled primary diffuse type 2 chronic rhinosinusitis. [PDF]

Eur Arch Otorhinolaryngol
Saccardo T, Roccuzzo G, Tessari N, Zampollo S, Fontana A, Scarpa B, Nicolai P, Ottaviano G.   +7 more
europepmc   +1 more source

Asthma heterogeneity and severity [PDF]

, 2016

core   +1 more source

Effective Use of Mepolizumab in a Rare Case of Eosinophilic Granulomatosis With Polyangiitis Complicated by Pulmonary Tuberculosis. [PDF]

Cureus
Okada Y, Kumamoto M, Muro S, Tamaki S.
europepmc   +1 more source

Biomarker-guided IL-5 blockade achieves steroid-free MPO-ANCA seroconversion in EGPA. [PDF]

J Allergy Clin Immunol Glob
Matsuno O, Wibowo T, Ishida Y, Ogata A.
europepmc   +1 more source

Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy. [PDF]

Front Allergy
Matsuno O, Kawamoto M, Wibowo T, Ishida Y, Ogata A.   +4 more
europepmc   +1 more source

COPD 2.0: Bronchodilators, biologics and beyond - A systematic review. [PDF]

Lung India
Shamim H, Singh AK, Sharma R, Mishra RK.
europepmc   +1 more source

Severe cutaneous adverse drug reactions due to antituberculosis drugs and their management. [PDF]

North Clin Istanb
Keren M, Aynaci A, Bulut I, Demir NC, Babalik A, Selcuk A.   +5 more
europepmc   +1 more source

Comparative analysis of the manufacturing carbon footprint of biologics for severe asthma. [PDF]

BMJ Open
Taylor H, Rahman N.
europepmc   +1 more source

Efficacy of Biologics on Nasal Symptoms in Severe Asthmatics: We Need Additional Biomarkers or Strategies to Assess Phenotypes or Endotypes. [PDF]

Allergy Asthma Immunol Res
Yong HJ, Jee YK.
europepmc   +1 more source